Akums Drugs rises on getting patent certificate from Government of India
Akums Drugs is currently trading at Rs. 911.65, up by 4.10 points or 0.45% from its previous closing of Rs. 907.55 on the BSE.
The scrip opened at Rs. 948.95 and has touched a high and low of Rs. 948.95 and Rs. 910.30 respectively. So far 7702 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1174.85 on 20-Aug-2024 and a 52 week low of Rs. 724.50 on 06-Aug-2024.
Last one week high and low of the scrip stood at Rs. 948.95 and Rs. 849.00 respectively. The current market cap of the company is Rs. 14441.69 crore.
The promoters holding in the company stood at 84.91%, while Non-Institutions held 15.09% in the company.
Akums Drugs & Pharmaceuticals has received Patent Certificate (enclosed) from the Patent Office, Government of India. The company has received Patent Certificate on September 12, 2024, for its invention titled ‘Room Stable Hydroxyurea Oral Suspension’ valid for a term of 20 years in accordance with the provisions of the Patents Act, 1970.
The Patent ‘Room Stable Hydroxyurea Oral Suspension’ is a breakthrough formulation aimed at managing Sickle Cell Disease (SCD). This development reinforces company’s role as an innovator in pharmaceutical solutions, offering a significant advance in addressing the storage and accessibility challenges associated with Hydroxyurea solution.
Akums Drugs & Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
